Executive Summary: The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year
LFP-09.01 — The Cost Drivers#
Specialty drugs account for 2 to 3 percent of prescription volume in commercially insured populations but consume more than half of total drug spending. For a small group level funded plan, the arithmetic is immediate and structural: one member beginning a biologic for rheumatoid arthritis at $6,500 per month can consume 42 percent of a 15-person plan’s $240,000 annual claims fund before any other medical costs are counted. This is not a rare edge case. It is the recurring exposure that defines specialty drug risk for small groups.
The dollar figures span a wide range but share a common trajectory. Adalimumab biosimilars now run $40,000 to $55,000 per year. Newer autoimmune and oncology therapies launch higher. The IQVIA Institute reported that the median annual treatment cost for new drugs launched in 2023 exceeded $150,000, with rare disease therapies routinely reaching $300,000 to $500,000. Total U.S. net pharmaceutical spending reached $487 billion in 2024, an 11.4 percent increase over 2023, the largest growth rate since the COVID-19 vaccine launches. IQVIA projects that figure will reach $600 billion by 2029.
The FDA approved 50 novel drugs in 2024, continuing a ten-year average of 46.5 annual approvals. Twenty-six of those 50 received orphan drug designation, a category that reliably generates therapies priced above $100,000 per year. The pipeline is accelerating the problem, not stabilizing it. For every dollar biosimilar competition saves on older reference biologics like adalimumab or infliximab, new approvals in oncology, rare disease, and neurology add multiples in new spending.
The stop loss architecture provides genuine protection: when a member breaches the specific attachment point, typically $75,000 for small groups, the stop loss carrier absorbs costs above the deductible. But the protection creates renewal consequences. If the drug was new or undisclosed at underwriting, the carrier responds with a laser at renewal, raising the specific attachment point for that member above expected claims and pushing the known annual drug cost back to the employer’s claims fund. Carriers including Sun Life, Voya, Symetra, and Tokio Marine HCC apply this approach routinely after specialty drug claims. The employer then faces three choices, none favorable: accept the laser, pay a substantially higher premium for no-laser coverage, or shop the group to a carrier that will laser the same risk after reviewing the claims history.
Plan design tools, including specialty tiers, prior authorization, step therapy, and copay accumulator programs, are necessary but insufficient. They manage cost distribution. They do not change the underlying price. A $100,000 drug remains $100,000 after prior authorization confirms clinical necessity. The specialty drug problem in small group level funded plans reflects the collision between pharmaceutical pricing trajectory and the small risk pool’s structural inability to absorb high-cost variance. Plan sponsors who do not understand this dynamic, particularly the laser mechanics at renewal, will be surprised by the consequences of a cost event they technically survived.